Joint Accreditation Statement
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008162-9999-21-2893-L01-P.
Type of Activity: Application
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.75 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.
The webinar is accessed through Zoom. An internet connection and the system requirements are needed to access the webinar.
Policy on Privacy and Confidentiality
Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.
Upon completion of this program, participants will be able to:
- Select appropriate diagnostics and biomarker testing for a patient being considered for immunotherapy based on the expert panel recommendations in the CPG
- Implement immunotherapy treatments effectively and appropriately according to the recommendations in the SITC CPG
- Appraise patterns of response to immunotherapy in order to appropriately monitor and manage patients during treatment
- Identify signs and symptoms of common immunotherapy-related toxicities and implement appropriate management strategies based on the EP recommendations
- Describe considerations and available tools to assess and support patient quality of life during immunotherapy treatment
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer
This webinar is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Celgene Corporation and Merck & Co., Inc.